A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3160
Full Text
Open PDFAbstract
Available in full text
Date
February 5, 2019
Authors
Publisher
American Association for Cancer Research (AACR)